Avalo Therapeutics (AVTX) Return on Invested Capital (2017 - 2025)
Historic Return on Invested Capital for Avalo Therapeutics (AVTX) over the last 9 years, with Q3 2025 value amounting to 0.68%.
- Avalo Therapeutics' Return on Invested Capital rose 161400.0% to 0.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68%, marking a year-over-year increase of 161400.0%. This contributed to the annual value of 0.98% for FY2024, which is 161300.0% down from last year.
- According to the latest figures from Q3 2025, Avalo Therapeutics' Return on Invested Capital is 0.68%, which was up 161400.0% from 0.53% recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Return on Invested Capital registered a high of 11.67% during Q3 2022, and its lowest value of 342.51% during Q2 2022.
- Moreover, its 5-year median value for Return on Invested Capital was 0.89% (2024), whereas its average is 19.04%.
- Its Return on Invested Capital has fluctuated over the past 5 years, first plummeted by -3397000bps in 2022, then skyrocketed by 3456400bps in 2023.
- Over the past 5 years, Avalo Therapeutics' Return on Invested Capital (Quarter) stood at 2.59% in 2021, then soared by 324bps to 5.79% in 2022, then crashed by -143bps to 2.49% in 2023, then skyrocketed by 64bps to 0.89% in 2024, then rose by 24bps to 0.68% in 2025.
- Its last three reported values are 0.68% in Q3 2025, 0.53% for Q2 2025, and 0.39% during Q1 2025.